160 related articles for article (PubMed ID: 22043925)
1. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates.
Sharp CP; Lail A; Donfield S; Gomperts ED; Simmonds P
Transfusion; 2012 Jul; 52(7):1482-9. PubMed ID: 22043925
[TBL] [Abstract][Full Text] [Related]
2. Human parvovirus 4 in the blood supply and transmission by pooled plasma-derived clotting factors: does it matter?
Delwart E
Transfusion; 2012 Jul; 52(7):1398-403. PubMed ID: 22780892
[No Abstract] [Full Text] [Related]
3. Assessing causality in the transmission of viruses by blood products.
Farrugia A; Gustafson M
Transfusion; 2012 Jul; 52(7):1598; author reply 1598-9. PubMed ID: 22780901
[No Abstract] [Full Text] [Related]
4. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies.
Sharp CP; Lail A; Donfield S; Simmons R; Leen C; Klenerman P; Delwart E; Gomperts ED; Simmonds P
J Infect Dis; 2009 Oct; 200(7):1119-25. PubMed ID: 19691429
[TBL] [Abstract][Full Text] [Related]
5. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
[TBL] [Abstract][Full Text] [Related]
6. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4.
Schneider B; Fryer JF; Oldenburg J; Brackmann HH; Baylis SA; Eis-Hübinger AM
Haemophilia; 2008 Sep; 14(5):978-86. PubMed ID: 18565125
[TBL] [Abstract][Full Text] [Related]
7. Comparison of GB virus C, HIV, and HCV infection markers in hemophiliacs exposed to non-inactivated or inactivated factor concentrates.
Kupfer B; Ruf T; Matz B; Nattermann J; Spengler U; Rockstroh JK; Brackmann HH; Blümel J; Tacke M; Kaiser R
J Clin Virol; 2005 Sep; 34(1):42-7. PubMed ID: 16087123
[TBL] [Abstract][Full Text] [Related]
8. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs.
Grosse-Bley A; Eis-Hübinger AM; Kaiser R; Oldenburg J; Brackmann HH; Schwarz TF; Schneweis KE
Thromb Haemost; 1994 Oct; 72(4):503-7. PubMed ID: 7878623
[TBL] [Abstract][Full Text] [Related]
9. Human parvovirus PARV4 in clotting factor VIII concentrates.
Fryer JF; Hubbard AR; Baylis SA
Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279
[TBL] [Abstract][Full Text] [Related]
10. Detection of human parvovirus 4 viremia in the follow-up blood samples from seropositive individuals suggests the existence of persistent viral replication or reactivation of latent viral infection.
Chen MY; Hung CC; Lee KL
Virol J; 2015 Jun; 12():94. PubMed ID: 26088443
[TBL] [Abstract][Full Text] [Related]
11. Parvovirus 4 in Individuals with Severe Hemophilia A and Matched Control Group.
Asiyabi S; Marashi SM; Vahabpour R; Nejati A; Azizi-Saraji A; Mustafa AS; Baghernejad A; Shoja Z; Mansouritorghabeh H
Int J Hematol Oncol Stem Cell Res; 2021 Jul; 15(3):192-198. PubMed ID: 35083000
[No Abstract] [Full Text] [Related]
12. Production of human parvovirus 4 VP2 virus-like particles in yeast and their evaluation as an antigen for detection of virus-specific antibodies in human serum.
Tamošiūnas PL; Simutis K; Kodzė I; Firantienė R; Emužytė R; Petraitytė-Burneikienė R; Zvirblienė A; Sasnauskas K
Intervirology; 2013; 56(5):271-7. PubMed ID: 23941824
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population.
Eis-Hübinger AM; Oldenburg J; Brackmann HH; Matz B; Schneweis KE
Zentralbl Bakteriol; 1996 Jul; 284(2-3):232-40. PubMed ID: 8837383
[TBL] [Abstract][Full Text] [Related]
14. Parvovirus B19 transmission by heat-treated clotting factor concentrates.
Blümel J; Schmidt I; Effenberger W; Seitz H; Willkommen H; Brackmann HH; Löwer J; Eis-Hübinger AM
Transfusion; 2002 Nov; 42(11):1473-81. PubMed ID: 12421221
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa.
Rubinstein R; Karabus CD; Smuts H; Kolia F; Van Rensburg EJ
Haemophilia; 2000 Mar; 6(2):93-7. PubMed ID: 10781195
[TBL] [Abstract][Full Text] [Related]
16. Human parvovirus B19 and parvovirus 4 among Iranian patients with hemophilia.
Javanmard D; Ziaee M; Ghaffari H; Namaei MH; Tavakoli A; Mollaei H; Moghoofei M; Mortazavi HS; Monavari SH
Blood Res; 2017 Dec; 52(4):311-315. PubMed ID: 29333409
[TBL] [Abstract][Full Text] [Related]
17. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
18. Lack of evidence for the transmission of hepatitis E virus by coagulation factor concentrates based on seroprevalence data.
Juhl D; Nowak-Göttl U; Blümel J; Görg S; Hennig H
Transfus Med; 2018 Dec; 28(6):427-432. PubMed ID: 29280212
[TBL] [Abstract][Full Text] [Related]
19. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates.
Bartolomei Corsi O; Azzi A; Morfini M; Fanci R; Rossi Ferrini P
J Med Virol; 1988 Jun; 25(2):165-70. PubMed ID: 2839609
[TBL] [Abstract][Full Text] [Related]
20. Absence of novel human parvovirus (PARV4) in Danish mothers and children.
von Linstow ML; Rosenfeldt V; Lindberg E; Jensen L; Hedman L; Li X; Väisänen E; Hedman K; Norja P
J Clin Virol; 2015 Apr; 65():23-5. PubMed ID: 25766982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
